PROGRAM Plus

Authorised

- Milbemycin oxime
- Lufenuron

Product identification

Medicine name:
PROGRAM Plus
INTERCEPTOR PLUS compresse rivestite da 11,5 mg/230 mg per cani

Active substance:
Milbemycin oxime

Lufenuron

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Milbemycin oxime
11.50 milligram(s) / 1.00 Tablet

Lufenuron
230.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Film-coated tablet

Withdrawal period by route of administration:

Oral use:

- **Dog**

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP54AB51

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Italy

Package description:

Carton container containing 8 pentagonal tablets in PVDC/PVC blisters, thermosealed with aluminium foil, boxed in a free-opening, labelled carton

Carton container containing 6 pentagonal tablets in PVDC/PVC blister, thermosealed with aluminium foil, boxed in a free-opening, labelled carton

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Elanco GmbH

Marketing authorisation date:

30/04/1998

Manufacturing sites for batch release:

Elanco France S.A.S

Responsible authority:
Ministry Of Health

Authorisation number:
102569

Date of authorisation status change:
14/01/2009

Reference member state:
Italy

Procedure number:
IT/V/0106/003

Concerned member states:
Austria Germany Portugal Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.